Overview

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:
0

Participant gender:
Female

Summary

The aim of this study is to : 1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy compared to methotrexate. 2. Use of the Gnrh antagonist for the treatment of ectopic pregnancy compared to methotrexate.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Aromatase Inhibitors
Cetrorelix
Letrozole
Methotrexate

Criteria

Inclusion Criteria:

- Patients who have undisturbed ectopic pregnancy .Who are:

1. have no significant pain

2. have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35mm
with no visible heartbeat

3. have a serum human chorionic gonadotropins level less than 1,500 IU/litre

4. do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) .

Exclusion Criteria:

1. An undisturbed ectopic pregnancy and significant pain

2. An undisturbed ectopic pregnancy with an adnexal mass of 35 mm or larger

3. An undisturbed ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan

4. An undisturbed ectopic pregnancy and a serum human chorionic gonadotropins level of
5,000 IU/litre or more

5. intrauterine pregnancy